IndiumV1, Main, Exploration, bibRecord, 000219

A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide

Identifieur interne : 000219 ( Main/Exploration ); précédent : 000218; suivant : 000220

A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide

Auteurs : RBID : ISTEX:259_1994_Article_BF00176572.pdf

English descriptors

KwdEn :
- Peptide, Radioindium labelled RC-160, Radiopharmaceutical, Somatostatin, Specific binding, Tumour imager.

Abstract

We have evaluated the potential usefulness of indium-111 labelled [DTPA-D-Phe1]RC-160, derived from the octapeptide somatostatin analogue RC-160, as a radiopharmaceutical for the in vivo detection of somatostatin receptor-positive tumours. For this purpose 111In-and 111In-labelled [DTPA-D-Phe1]RC-160 was tested for its biological activity, and applied for somatostatin receptor scintigraphy in vivo to rats bearing the transplantable rat pancreatic tumour CA20948, which expresses somatostatin receptors. We previously described the development of the 111In-labelled somatostatin analogue [DTPA-D-Phe1]octreotide and its use in the in vivo visualization of somatostatin receptor-positive tumours in rats and in humans. Like [111In-DTPA-D-Phe1]octreotide, [111In-DTPA-D-Phe1]RC-160 showed uptake in and specific binding in vivo to somatostatin receptor-positive organs and tumours, and the tumours were clearly visualized by gamma camera scintigraphy. However, as compared to [111In-DTPA-D-Phe1]octreotide, blood radioactivity (background) was higher, resulting in a lower tumour to blood (background) ratio. Using this animal model we therefore conclude that [111In-DTPA-DPhe1]RC-160 has no advantage over [111In-DTPA-DPhe1]octreotide as a radiopharmaceutical in the visualization of somatostatin receptors which bind both analogues. However, recent reports suggest the existence of different somatostatin receptor subtypes on some human cancers, which differentially bind RC-160 and not octreotide. These tumours include cancers of the breast, ovary, exocrine pancreas, prostate and colon. [111In-DTPA-D-Phe1]RC-160 might be of interest for future use in such cancer patients as a radiopharmaceutical for imaging somatostatin receptor-positive tumours, which do not bind octreotide.

DOI: 10.1007/BF00176572

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000B98
to stream Main, to step Curation: 000B98

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title>A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide</title>
<author><name>W. A. P. Breeman</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>L. J. Hofland</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>M. van der Pluijm</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>P. M. van Koetsveld</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>M. de Jong</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>B. Setyono-Han</name>
<affiliation wicri:level="1"><mods:affiliation>Dr. Daniël den Hoed Cancer Centre, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Dr. Daniël den Hoed Cancer Centre, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>W. H. Bakker</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>D. J. Kwekkeboom</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>T. J. Visser</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>S. W. J. Lamberts</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>E. P. Krenning</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="RBID">ISTEX:259_1994_Article_BF00176572.pdf</idno>
<date when="1994">1994</date>
<idno type="doi">10.1007/BF00176572</idno>
<idno type="wicri:Area/Main/Corpus">000B98</idno>
<idno type="wicri:Area/Main/Curation">000B98</idno>
<idno type="wicri:Area/Main/Exploration">000219</idno>
</publicationStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Peptide</term>
<term>Radioindium labelled RC-160</term>
<term>Radiopharmaceutical</term>
<term>Somatostatin</term>
<term>Specific binding</term>
<term>Tumour imager</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="eng">We have evaluated the potential usefulness of indium-111 labelled [DTPA-D-Phe1]RC-160, derived from the octapeptide somatostatin analogue RC-160, as a radiopharmaceutical for the in vivo detection of somatostatin receptor-positive tumours. For this purpose 111In-and 111In-labelled [DTPA-D-Phe1]RC-160 was tested for its biological activity, and applied for somatostatin receptor scintigraphy in vivo to rats bearing the transplantable rat pancreatic tumour CA20948, which expresses somatostatin receptors. We previously described the development of the 111In-labelled somatostatin analogue [DTPA-D-Phe1]octreotide and its use in the in vivo visualization of somatostatin receptor-positive tumours in rats and in humans. Like [111In-DTPA-D-Phe1]octreotide, [111In-DTPA-D-Phe1]RC-160 showed uptake in and specific binding in vivo to somatostatin receptor-positive organs and tumours, and the tumours were clearly visualized by gamma camera scintigraphy. However, as compared to [111In-DTPA-D-Phe1]octreotide, blood radioactivity (background) was higher, resulting in a lower tumour to blood (background) ratio. Using this animal model we therefore conclude that [111In-DTPA-DPhe1]RC-160 has no advantage over [111In-DTPA-DPhe1]octreotide as a radiopharmaceutical in the visualization of somatostatin receptors which bind both analogues. However, recent reports suggest the existence of different somatostatin receptor subtypes on some human cancers, which differentially bind RC-160 and not octreotide. These tumours include cancers of the breast, ovary, exocrine pancreas, prostate and colon. [111In-DTPA-D-Phe1]RC-160 might be of interest for future use in such cancer patients as a radiopharmaceutical for imaging somatostatin receptor-positive tumours, which do not bind octreotide.</div>
</front>
</TEI>
<mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="d10cdfff58ce54720d921a88591e16eeedc87d69"><titleInfo lang="eng"><title>A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide</title>
</titleInfo>
<name type="personal"><namePart type="given">W. A. P.</namePart>
<namePart type="family">Breeman</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">L. J.</namePart>
<namePart type="family">Hofland</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">M.</namePart>
<namePart type="family">van der Pluijm</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">P. M.</namePart>
<namePart type="family">van Koetsveld</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">M.</namePart>
<namePart type="family">de Jong</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">B.</namePart>
<namePart type="family">Setyono-Han</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Dr. Daniël den Hoed Cancer Centre, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">W. H.</namePart>
<namePart type="family">Bakker</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">D. J.</namePart>
<namePart type="family">Kwekkeboom</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">T. J.</namePart>
<namePart type="family">Visser</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">S. W. J.</namePart>
<namePart type="family">Lamberts</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">E. P.</namePart>
<namePart type="family">Krenning</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands</affiliation>
<affiliation>Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<typeOfResource>text</typeOfResource>
<genre>Original Articles</genre>
<genre>Original Paper</genre>
<originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher>
<dateCreated encoding="w3cdtf">1993-09-06</dateCreated>
<dateValid encoding="w3cdtf">2004-07-05</dateValid>
<copyrightDate encoding="w3cdtf">1994</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="eng">We have evaluated the potential usefulness of indium-111 labelled [DTPA-D-Phe1]RC-160, derived from the octapeptide somatostatin analogue RC-160, as a radiopharmaceutical for the in vivo detection of somatostatin receptor-positive tumours. For this purpose 111In-and 111In-labelled [DTPA-D-Phe1]RC-160 was tested for its biological activity, and applied for somatostatin receptor scintigraphy in vivo to rats bearing the transplantable rat pancreatic tumour CA20948, which expresses somatostatin receptors. We previously described the development of the 111In-labelled somatostatin analogue [DTPA-D-Phe1]octreotide and its use in the in vivo visualization of somatostatin receptor-positive tumours in rats and in humans. Like [111In-DTPA-D-Phe1]octreotide, [111In-DTPA-D-Phe1]RC-160 showed uptake in and specific binding in vivo to somatostatin receptor-positive organs and tumours, and the tumours were clearly visualized by gamma camera scintigraphy. However, as compared to [111In-DTPA-D-Phe1]octreotide, blood radioactivity (background) was higher, resulting in a lower tumour to blood (background) ratio. Using this animal model we therefore conclude that [111In-DTPA-DPhe1]RC-160 has no advantage over [111In-DTPA-DPhe1]octreotide as a radiopharmaceutical in the visualization of somatostatin receptors which bind both analogues. However, recent reports suggest the existence of different somatostatin receptor subtypes on some human cancers, which differentially bind RC-160 and not octreotide. These tumours include cancers of the breast, ovary, exocrine pancreas, prostate and colon. [111In-DTPA-D-Phe1]RC-160 might be of interest for future use in such cancer patients as a radiopharmaceutical for imaging somatostatin receptor-positive tumours, which do not bind octreotide.</abstract>
<subject lang="eng"><genre>Key words</genre>
<topic>Radioindium labelled RC-160</topic>
<topic>Somatostatin</topic>
<topic>Specific binding</topic>
<topic>Tumour imager</topic>
<topic>Radiopharmaceutical</topic>
<topic>Peptide</topic>
</subject>
<relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title>
</titleInfo>
<titleInfo><title>European Journal of Nuclear Medicine</title>
<partNumber>Year: 1994</partNumber>
<partNumber>Volume: 21</partNumber>
<partNumber>Number: 4</partNumber>
</titleInfo>
<genre>Archive Journal</genre>
<originInfo><dateIssued encoding="w3cdtf">1994-04-01</dateIssued>
<copyrightDate encoding="w3cdtf">1994</copyrightDate>
</originInfo>
<subject usage="primary"><topic>Medicine & Public Health</topic>
<topic>Imaging / Radiology</topic>
<topic>Nuclear Medicine</topic>
</subject>
<identifier type="issn">0340-6997</identifier>
<identifier type="issn">Electronic: 1619-7089</identifier>
<identifier type="matrixNumber">259</identifier>
<identifier type="local">IssueArticleCount: 19</identifier>
<recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="doi">10.1007/BF00176572</identifier>
<identifier type="matrixNumber">Art8</identifier>
<identifier type="local">BF00176572</identifier>
<accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition>
<accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition>
<accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition>
<part><extent unit="pages"><start>328</start>
<end>335</end>
</extent>
</part>
<recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin>
<recordIdentifier>259_1994_Article_BF00176572.pdf</recordIdentifier>
</recordInfo>
</mods>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000219 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000219 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:259_1994_Article_BF00176572.pdf
   |texte=   A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide
}}

This area was generated with Dilib version V0.5.81.
Data generation: Mon Aug 25 10:35:12 2014. Site generation: Thu Mar 7 10:08:40 2024

	Serveur d'exploration sur l'Indium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'Indium

A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide

A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri